A Prospective, Single-center, Single-arm, Exploratory Study on the Treatment of Recurrent Glioblastoma With Tumor Electric Fields Treatment System

Xiangya Hospital of Central South University1 site in 1 country5 target enrollmentApril 7, 2020

ConditionsGlioblastoma

Overview

Phase: Early Phase 1
Intervention: Not specified
Conditions: Glioblastoma
Sponsor: Xiangya Hospital of Central South University
Enrollment: 5
Locations: 1
Primary Endpoint: The treatment-related adverse events
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.

Detailed Description

Subjects who have previously completed radiotherapy and at least two cycles of chemotherapy with imaging or pathological evidence of tumor recurrence will receive Tumor Electric Fields Treatment System. The main objective is to evaluate the safety of applying the Tumor Electric Fields Treatment System to subjects with recurrent GBM.

Registry

clinicaltrials.gov

Start Date

April 7, 2020

End Date

May 2021

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Xiangya Hospital of Central South University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with pathological diagnosis of glioblastoma at first surgery (WHO Grade IV, supratentorial location);
•Age between 18 and 65 years, male or female;
•Previously completed radiotherapy and at least two cycles of chemotherapy;
•With imaging or pathological evidence of tumor recurrence;
•Karnofsky performance score (KPS) score ≥ 70 before intervention;
•With a life expectancy more than 3 months;
•Adopted effective contraceptive measures at child-bearing age;
•Provided written informed consent.

Exclusion Criteria

•Patients unwilling to use the equipment ≥ 18h per day;
•With poor compliance or live too far from the research center, who cannot keep regular follow-up or adjust the electrode position of the treatment equipment, and who refuse to receive follow-up to terminal survival;
•With poor healing of scalp wound, poor scalp condition, large skull defect or other cases where electrodes are not suitable for wearing;
•Within 3 months from radiotherapy;
•Within 4 weeks from the last cycle of chemotherapy;
•Within 4 weeks from surgery for recurrence;
•Participated in other clinical trials.
•Pregnant;
•Epilepsy symptoms not effectively controlled;
•Blood and biochemical indicators in the following range: A. Liver function impairment: AST or ALT \> 3 times the upper limit of normal; B. Total bilirubin\> upper limit of normal value; C. Renal impairment: serum creatinine\>1.7mg /dL (\>150 mol/L); D. Coagulopathy: PT or APTT \>1.5 times normal; E. Platelets counts \< 100x10\^9/L; F. Absolute neutrophils count \< 1x10\^9/L; G. Hemoglobin \< 100g/L;